---
id: esmo-colorectal-metastatic-2023
title: "ESMO Clinical Practice Guideline: Metastatic Colorectal Cancer"
short_title: "ESMO mCRC 2023"

organization: European Society for Medical Oncology
collaborators: null
country: null
url: https://www.esmo.org/living-guidelines/esmo-metastatic-colorectal-cancer-living-guideline
doi: 10.1016/j.annonc.2022.10.003
pmid: 36307056
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - metastatic colorectal cancer
  - mCRC
tags:
  - RAS mutations
  - BRAF V600E
  - MSI/dMMR
  - bevacizumab

publication_date: 2023-01-01
previous_version_date: 2022-10-01
status: current
supersedes: esmo-colorectal-2022
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

# ESMO Clinical Practice Guideline: Metastatic Colorectal Cancer

## Scope
Evidence-based recommendations for diagnosis, treatment, and follow-up of metastatic colorectal cancer (mCRC).

## Key Recommendations

### Molecular Testing

#### Required Testing (Strong)
| Biomarker | Purpose |
|-----------|---------|
| RAS (KRAS/NRAS) | Anti-EGFR eligibility |
| BRAF V600E | Prognosis, targeted therapy |
| MSI/dMMR | Immunotherapy eligibility |
| HER2 amplification | Targeted therapy |
| NTRK fusions | TRK inhibitors |

#### Testing Recommendations
- Perform molecular profiling at diagnosis of metastatic disease
- Use NGS panel when available
- Liquid biopsy acceptable if tissue unavailable

### First-Line Treatment

#### MSI-H/dMMR mCRC
- **Pembrolizumab monotherapy** (preferred)
- Nivolumab ± ipilimumab (alternative)
- Superior to chemotherapy in first-line

#### RAS Wild-Type, Left-Sided
| Regimen | Notes |
|---------|-------|
| FOLFOX/FOLFIRI + anti-EGFR | Cetuximab or panitumumab |
| FOLFOXIRI + anti-EGFR | Selected fit patients |

#### RAS Wild-Type, Right-Sided
| Regimen | Notes |
|---------|-------|
| FOLFOX/FOLFIRI + bevacizumab | Anti-VEGF preferred |
| FOLFOXIRI + bevacizumab | High tumor burden |

#### RAS Mutant
| Regimen | Notes |
|---------|-------|
| FOLFOX/FOLFIRI + bevacizumab | Standard |
| FOLFOXIRI + bevacizumab | Fit patients |

### BRAF V600E Mutated mCRC

#### First-Line
- FOLFOXIRI + bevacizumab (aggressive approach)
- Standard doublet + bevacizumab

#### Second-Line and Beyond
- **Encorafenib + cetuximab** (BEACON regimen)
- May add binimetinib

### HER2-Amplified mCRC

#### Later Lines
- Trastuzumab + pertuzumab
- Trastuzumab + lapatinib
- Trastuzumab deruxtecan

### Oligometastatic Disease

#### Liver-Limited Metastases
- Multidisciplinary evaluation for resectability
- Perioperative chemotherapy (FOLFOX)
- Consider conversion chemotherapy if initially unresectable

#### Lung Metastases
- Surgery or ablation if technically feasible
- Systemic therapy as for other mCRC

### Second-Line Treatment

#### After First-Line Progression
| Prior Regimen | Second-Line Options |
|---------------|---------------------|
| Oxaliplatin-based | Irinotecan-based ± biologic |
| Irinotecan-based | Oxaliplatin-based ± biologic |

#### Biologic Continuation
- Continue bevacizumab beyond progression (switch chemotherapy backbone)
- Consider anti-EGFR if RAS WT and not previously used

### Third-Line and Beyond

#### Regorafenib
- Multi-kinase inhibitor
- OS benefit in refractory mCRC
- Manage hand-foot syndrome, hypertension

#### Trifluridine/Tipiracil (TAS-102)
- Fluoropyrimidine-based agent
- Improves OS in refractory setting
- May combine with bevacizumab

#### Fruquintinib
- VEGFR inhibitor
- Recently approved for refractory mCRC

### Immunotherapy in MSS mCRC
- Generally not effective as monotherapy
- Clinical trials exploring combinations
- Consider for TMB-high tumors

### Local Therapies

#### Hepatic Metastases
- Resection if feasible
- Ablation for small lesions
- Hepatic artery infusion (selected centers)
- SBRT/radiation

#### Peritoneal Metastases
- Consider CRS + HIPEC in selected patients
- Systemic therapy mainstay for most

### Supportive Care
- Pain management
- Nutritional support
- Management of bowel obstruction
- Palliative care integration

### Monitoring
- CT scans every 2-3 months during active treatment
- CEA monitoring (if elevated at baseline)
- Clinical assessment for toxicity

